Experience in the chemotherapy of severe, inoperable echinococcosis in man.
The effect of albendazole and mebendazole was studied in 25 patients with severe, multiple, inoperable echinococcosis. Eleven patients were treated with albendazole 10 mg/kg/day for four courses of 30 days with 15-day drug-free intervals and 14 with mebendazole 50-70 mg/kg/day continuously for between 6 and 24 months. The determination of cyst response was based on the changes in cyst appearance as seen by radiography, ultrasound and computed tomography. Albendazole and mebendazole were found to have favourable effects in patients with severe, inoperable hydatid disease, although the degree of response varied. Treatment with albendazole was successful in seven cases, partially successful in two, and failure was noted in the other two patients. In patients treated with mebendazole, success was established in three, partial success in five and failure in six cases. The differences in response were mainly associated with cyst condition and the drug used. In some cases long-term therapy and retreatment should be recommended.
Todorov
T
T
Institute of Pharmacology, Medical Academy, Sofia, Bulgaria.
Vutova
K
K
Mechkov
G
G
Tonchev
Z
Z
Georgiev
P
P
Lazarova
I
I
D000328:Adult; D000368:Aged; D015766:Albendazole / Q000627:therapeutic use*; D001927:Brain Diseases / Q000188:drug therapy / Q000473:pathology; D002648:Child; D002675:Child, Preschool; D004443:Echinococcosis / Q000188:drug therapy* / Q000473:pathology; D004444:Echinococcosis, Hepatic / Q000188:drug therapy / Q000473:pathology; D004445:Echinococcosis, Pulmonary / Q000188:drug therapy / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008463:Mebendazole / Q000627:therapeutic use*; D008875:Middle Aged; D013158:Splenic Diseases / Q000188:drug therapy / Q000473:pathology
D008463:Mebendazole; D015766:Albendazole